New Notices
- Updated General Chapter Prospectus: <1568> Quality Considerations for Cannabis and Cannabis-derived Products for Clinical Research (updated 30-Jun-2022; input deadline 31-Jul-2022)
- New Notice of Intent to Revise: Upcoming Changes to USP's Description and Relative Solubility Reference Table (posted 24-Jun-2022)
- New General Chapter Prospectus: <1154> Liposome Drug Products (posted 24-Jun-2022; input deadline 24-Jul-2022)
- New General Announcement: USP General Notices Biologics Nomenclature (posted 06-Jun-2022)
- New Notice of Intent to Revise: <711> Dissolution (posted 27-May-2022)
- New Notice of Intent to Revise: Isotretinoin Capsules (posted 27-May-2022)
- New Notice of Intent to Revise: Ziprasidone Hydrochloride (posted 27-May-2022)
- New Notice of Intent to Revise: Phenelzine Sulfate (posted 29-Apr-2022)
- New General Announcement: Official Dates for Redesigned Formats (posted 29-Apr-2022)
- New Publication Announcement: Monographs Affected by Revision to <211> Arsenic (posted 29-Apr-2022)
- New Publication Announcement: Monographs Affected by Revision to <251> Lead (posted 29-Apr-2022)
- New Publication Announcement: Monographs Affected by Revision to <261> Mercury (posted 29-Apr-2022)
- New Publication Announcement: Monographs Affected by Revision to <206> Aluminum (posted 29-Apr-2022)
- New Publication Announcement: Monographs Affected by Revision to <241> Iron (posted 29-Apr-2022)
- New Publication Announcement: Monographs Affected by Revision to <291> Selenium (posted 29-Apr-2022)
- New General Announcement: Analytical Procedures for Viral Vectored Vaccine Quality (posted 29-Apr-2022)
- New General Chapter Prospectus: <1114> Ensuring Microbiological Quality of Articles of Botanical Origin General Chapter Prospectus (posted 29 Apr-2022)
- New Notice of Intent to Revise: <411> Folic Acid Assay and Folic Acid Tablets (posted 22–Apr–2022)
- New Notice of Intent to Revise: Levalbuterol Hydrochloride (posted 22–Apr–2022)
- New Notice of Intent to Revise: Levalbuterol Inhalation Solution (posted 22–Apr–2022)
- New Notice of Intent to Revise: Mitotane (posted 21–Apr–2022)
- New Notice of Intent to Revise: Mitotane Tablets (posted 21–Apr–2022)
- New Notice of Intent to Revise: Vancomycin Injection (posted 25–Mar–2022)
- New General Announcement: New Process and New Revision Markup for Chemical Information Updates in USP–NF (posted 25–Mar–2022)
- Monographs appearing in redesigned format as of USP–NF 2022, Issue 2 (posted 25–Mar–2022)
- New Notice of Intent to Revise: <665> Plastic Components and Systems Used to Manufacture Pharmaceutical Drug Products and Biopharmaceutical Drug Substances and Products (posted 25–Feb–2022)
- New Notice of Intent to Revise: Acyclovir (posted 25–Feb–2022)
- New Notice of Intent to Revise: Dextrose Injection (posted 25–Feb–2022)
- Updated Notice of Intent to Revise: Acetaminophen (posted 28–Jan–2022; update 11–Feb–2022)
- Updated Notice of Intent to Revise: Dextran 40 and Dextran 70 (posted 28–Jan–2022; updated 11–Feb–2022)
- New General Announcement: Analytical Procedures for mRNA Vaccine Quality (Draft Guidelines)- posted 10–Feb–2022
- New Publication Announcement: Update on Delayed Implementation for Sennosides (posted 01–Feb–2022)
- Updated Notice of Intent to Revise: <711> Dissolution (posted 29–Oct–2021; updated 28–Jan–2022)
- New Notice of Intent to Revise: Enoxaparin Sodium, <209> Low Molecular Weight Heparin Molecular Weight Determinations and Dalteparin Sodium (posted 28–Jan–2022)
- New Notice of Intent to Revise: Monographs Affected by Revision to <785> Osmolality and Osmolarity (posted 28–Jan–2022)
- Updated Notice of Intent to Revise: Magnesium Sulfate (posted 30–Dec–2021; updated 28–Jan–2022)
- New Notice of Intent to Revise: Gramicidin (posted 21–Jan–2022)
- New Publication Announcement: Public Comment Period Extended- Revisions to <795> and <797> (posted 14–Jan–2022)
- New Notice of Intent to Revise: Prazosin Hydrochloride (posted 03–Jan–2022)